PART I Overview We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance. The DNase technology is designed to targe...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001683168-26-001737 | EDGAR | 67K words |
| 2025-03-18 | 2024-12-31 | 0001683168-25-001686 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001683168-24-001594 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0001683168-23-001674 | EDGAR | — |
| 2022-03-22 | 2021-12-31 | 0001683168-22-001839 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001683168-21-000969 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001683168-20-000967 | EDGAR | — |
| 2019-03-29 | 2018-12-31 | 0001683168-19-000840 | EDGAR | — |
| 2018-03-30 | 2017-12-31 | 0001683168-18-000831 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001683168-17-000749 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001683168-26-006061 | EDGAR | — |
| 2025-11-12 | 2025-09-30 | 0001683168-25-008259 | EDGAR | 14K words |
| 2025-08-12 | 2025-06-30 | 0001683168-25-005983 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001683168-25-003496 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001683168-24-007903 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001683168-24-005572 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001683168-24-003172 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001683168-23-007820 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001683168-23-005513 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001683168-23-003201 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001683168-22-007447 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001683168-22-005567 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-07 | 0001683168-26-006077 | EDGAR | — |
| 2026-03-13 | 0001683168-26-001744 | EDGAR | 1K words |
| 2026-01-09 | 0001683168-26-000196 | EDGAR | — |
| 2025-12-11 | 0001683168-25-009076 | EDGAR | — |
| 2025-11-13 | 0001683168-25-008288 | EDGAR | — |
| 2025-10-14 | 0001683168-25-007528 | EDGAR | — |
| 2025-08-13 | 0001683168-25-006001 | EDGAR | — |
| 2025-05-14 | 0001683168-25-003513 | EDGAR | — |
| 2025-04-10 | 0001683168-25-002396 | EDGAR | — |
| 2025-03-19 | 0001683168-25-001693 | EDGAR | — |
252 total filings indexed. 220 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534525 |
| Ticker | XBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.xeneticbio.com |
| Listed | 2012-05-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XBIO (~200 tokens, structured JSON with cryptographic provenance)